Greenwich LifeSciences wins UK regulatory clearance to expand FLAMINGO-01 trial

Reuters2026/07/22 10:00

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Greenwich Lifesciences won UK regulatory clearance to expand its Phase III FLAMINGO-01 breast cancer recurrence trial into the United Kingdom.
The authorization adds 5-10 potential UK sites to roughly 170-180 active sites across the US and Europe.
The company is working with The Royal Marsden to advance site start-up and oversight in the UK.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Greenwich Lifesciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607220600PRIMZONEFULLFEED9766198) on July 22, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Greenwich LifeSciences wins UK regulatory clearance to expand FLAMINGO-01 trial

You may also like

Crypto prices